Cihan ASLAN, Mehmet Fatih ÜNAL, Bahadır KONUŞKAN, Burçin ŞENER

Comparison of serum anti-neuronal antibody levels in patients having autism spectrum disorder with and without regression

Background. Autism Spectrum Disorders (ASD) may present with a delay in social and communication development, or less frequently, with regression in social and language skills. The reasons for this difference in clinical presentation are unknown, and the regressive symptoms in the second group suggest an acquired process. Methods. We investigated serum autoantibodies in these two types of ASD in a cross-sectional design in a total of 50 children, 24 with autistic regression and 26 with classical ASD according to the DSM-5 criteria. Clinical assessment by the Childhood Autism Rating Scale (CARS) and Ankara Developmental Screening Test (ADST), parental questionnaires consisting of the Aberrant Behavior Checklist (ABC) and Autism Behavior Checklist (AuBC) were completed. Serum samples were tested for anti-neuronal antibodies including anti-N-methyl-Daspartate receptor (NMDAR), anti-contactin-associated protein (CASPR2), anti-leucine rich glioma inactivated 1 (LG1), anti-glutamate type 2-amino-3-propionic Acid (AMPA) 1-2, anti-gamma amino butyric acid (GABA) B, anti-dipeptidyl aminopeptidase-like protein 6 (DPPX) and anti-glutamic acid decarboxylase 65(GAD). Results. Serum anti-GAD antibodies were at detectable levels in five (20.8%) patients with autistic regression, of whom three had 2 to 4-fold increased titers, and in none of the patients with classical ASD. The age of the father at the patient’s birth and the duration of autistic regression correlated with anti-GAD IgG levels (P: 0,045, P: 0.855 respectively) in the ASD-regression group. No other antibodies were detected in either group. Conclusions. Our results do not suggest a causative role of anti-neuronal antibodies, but the possibility of an autoimmune process accompanying regressive symptoms in a small subgroup of ASD.

PDF

___

1. Barger BD, Campbell JM, McDonough JD. Prevalence and onset of regression within autism spectrum disorders: a meta-analytic review. J Autism Dev Disord 2013; 43: 817-828.

2. Jones LA, Campbell JM. Clinical characteristics associated with language regression for children with autism spectrum disorders. J Autism Dev Disord 2010; 40: 54-62.

3. Hughes HK, Mills Ko E, Rose D, Ashwood P. Immune dysfunction and autoimmunity as pathological mechanisms in autism spectrum disorders. Front Cell Neurosci 2018; 12: 405.

4. Zou T, Liu J, Zhang X, Tang H, Song Y, Kong X. Autoantibody and autism spectrum disorder: a systematic review. Res Autism Spectr Disord 2020; 75: 101568.

5. Saghazadeh A, Ataeinia B, Keynejad K, Abdolalizadeh A, Hirbod-Mobarakeh A, Rezaei N. A meta-analysis of pro-inflammatory cytokines in autism spectrum disorders: effects of age, gender, and latitude. J Psychiatr Res 2019; 115: 90-102.

6. Prosperi M, Guiducci L, Peroni DG, et al. Inflammatory biomarkers are correlated with some forms of regressive autism spectrum disorder. Brain Sci 2019; 9: 366.

7. Han YM, Chan AS, Sze SL, et al. Altered immune function associated with disordered neural connectivity and executive dysfunctions: a neurophysiological study on children with autism spectrum disorders. Res Autism Spectr Disord 2013; 7: 662-674.

8. Boterberg S, Charman T, Marschik PB, Bölte S, Roeyers H. Regression in autism spectrum disorder: a critical overview of retrospective findings and recommendations for future research. Neurosci Biobehav Rev 2019; 102: 24-55.

9. Morgan JT, Chana G, Pardo CA, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry 2010; 68: 368-376.

10. Won H, Lee HR, Gee HY, et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 2012; 486: 261-265.

11. Hacohen Y, Wright S, Gadian J, et al. N‐methyl‐d‐ aspartate (NMDA) receptor antibodies encephalitis mimicking an autistic regression. Dev Med Child Neurol 2016; 58: 1092-1094.

12. Caraballo RH, Cejas N, Chamorro N, Kaltenmeier MC, Fortini S, Soprano AM. Landau–Kleffner syndrome: a study of 29 patients. Seizure 2014; 23: 98-104.

13. Ozonoff S, Williams BJ, Landa R. Parental report of the early development of children with regressive autism: the delays-plus-regression phenotype. Autism 2005; 9: 461-486.

14. Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord 1980; 10: 91-103.

15. Savasır I, Sezgin N, Erol N. Ankara Gelişim Tarama Envanteri. (3. Basım) Ankara: Türk Psikologlar Derneği Yayınları, 1998.

16. Krug DA, Arick J, Almond P. Behavior checklist for identifying severely handicapped individuals with high levels of autistic behavior. J Child Psychol Psychiatry 1980; 21: 221-229.

17. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89: 485-491.

18. Ricken G, Schwaiger C, De Simoni D, et al. Detection methods for autoantibodies in suspected autoimmune encephalitis. Front Neurol 2018; 9: 841.

19. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010; 67: 470-478.

20. Chen MH, Su TP, Chen YS, et al. Comorbidity of allergic and autoimmune diseases in patients with autism spectrum disorder: a nationwide populationbased study. Res Autism Spectr Disord 2013; 7: 205- 212.

21. Scott O, Shi D, Andriashek D, Clark B, Goez HR. Clinical clues for autoimmunity and neuroinflammation in patients with autistic regression. Dev Med Child Neurol 2017; 59: 947-951.

22. Ozonoff S, Iosif AM, Young GS, et al. Onset patterns in autism: correspondence between home video and parent report. J Am Acad Child Adolesc Psychiatry 2011; 50: 796-806.e1.

23. Young AM, Chakrabarti B, Roberts D, Lai MC, Suckling J, Baron-Cohen S. From molecules to neural morphology: understanding neuroinflammation in autism spectrum condition. Mol Autism 2016; 7: 9.

24. Brenton JN, Goodkin HP. Antibody-mediated autoimmune encephalitis in childhood. Pediatr Neurol 2016; 60: 13-23.

25. Scott O, Richer L, Forbes K, et al. Anti–N-methyl-Daspartate (NMDA) receptor encephalitis: an unusual cause of autistic regression in a toddler. J Child Neurol 2014; 29: 691-694.

26. Hacohen Y, Wright S, Gadian J, et al. N-methyl-daspartate (NMDA) receptor antibodies encephalitis mimicking an autistic regression. Dev Med Child Neurol 2016; 58: 1092-1094.

27. Peñagarikano O, Geschwind DH. What does CNTNAP2 reveal about autism spectrum disorder? Trends Mol Med 2012; 18: 156-163.

28. Oblak AL, Gibbs TT, Blatt GJ. Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. J Neurochem 2010; 114: 1414-1423.

29. O’Connor EC, Bariselli S, Bellone C. Synaptic basis of social dysfunction: a focus on postsynaptic proteins linking group‐I mGluRs with AMPARs and NMDARs. Eur J Neurosci 2014; 39: 1114-1129.

30. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13: 167-177.

31. Cambuli VM, Incani M, Cossu E, et al. Prevalence of type 1 diabetes autoantibodies (GADA, IA2, and IAA) in overweight and obese children. Diabetes Care 2010; 33: 820-822.

32. Menon D, Menon RN, Kumar H, et al. The expanding spectrum of pediatric anti-glutamic acid decarboxylase antibody mediated CNS disease-a chance association? Neuroimmunol Neuroinflamm 2016; 3: 219-224.

33. Rout UK, Dhossche DM. A pathogenetic model of autism involving Purkinje cell loss through antiGAD antibodies. Med Hypotheses 2008; 71: 218-221.

34. Najjar S, Pearlman D, Devinsky O, et al. Neuropsychiatric autoimmune encephalitis without VGKC-complex, NMDAR, and GAD autoantibodies: case report and literature review. Cogn Behav Neuro 2013; 26: 36-49.

35. Gresa-Arribas N, Ariño H, Martínez-Hernández E, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS One. 2015; 10: e0121364.

36. Rout UK, Mungan NK, Dhossche DM. Presence of GAD65 autoantibodies in the serum of children with autism or ADHD. Eur ChildAdolesc Psychiatry 2012; 21: 141-147.

37. Jarius S, Stich O, Speck J, et al. Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol 2010; 229: 219-224.

38. Fatemi SH. Cerebellar pathology in autism. In: Gruol DL, Koibuchi N, Manto M, Molinari M, Schmahmann JD, Shen Y (eds). Essentials of Cerebellum and Cerebellar Disorders. Switzerland: Springer, 2016: 539-543.

39. Haberlandt E, Bast T, Ebner A, et al. Limbic encephalitis in children and adolescents. Arch Dis Child 2011; 96: 186-191.

40. Kalra S, Burbelo PD, Bayat A, et al. No evidence of antibodies against GAD65 and other specific antigens in children with autism. BBA Clin 2015; 4: 81-84.

41. Bayram AK, Kardas F, Demirci EO, et al. Lack of serum antineuronal antibodies in children with autism. Bratisl Lek Listy 2016; 117: 77-79.

42. Hamed NO, Al-Ayadhi L, Osman MA, et al. Understanding the roles of glutamine synthetase, glutaminase, and glutamate decarboxylase autoantibodies in imbalanced excitatory/inhibitory neurotransmission as etiological mechanisms of autism. Psychiatry Clin Neurosci 2018; 72: 362-373.

43. Stefanatos G. Changing perspectives on LandauKleffner syndrome. Clin Neuropsychol 2011; 25: 963-988.

44. Shenoy S, Arnold S, Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr 2000; 136: 682-687.

45. Duffy FH, Shankardass A, McAnulty GB, et al. Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior. BMC Neurol 2014; 14: 70.

46. Malek M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi MR, Akhondzadeh S. Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. Clin Neuropharmacol 2020; 43: 39-45.

47. Connery K, Tippett M, Delhey LM, et al. Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. Transl Psychiatry 2018; 8: 148.

48. Hafizi S, Tabatabaei D, Lai MC. Review of clinical studies targeting inflammatory pathways for individuals with autism. Front Psychiatry 2019; 10: 849.

49. Ozonoff S, Li D, Deprey L, Hanzel EP, Iosif AM. Reliability of parent recall of symptom onset and timing in autism spectrum disorder. Autism 2018; 22: 891-896.

50. Pearson N, Charman T, Happé F, Bolton PF, McEwen FS. Regression in autism spectrum disorder: reconciling findings from retrospective and prospective research. Autism Res 2018; 11: 1602- 1620.